News
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Imugene.
RELATED STOCKHEAD STORIES
Health & Biotech
Check Up: Biden-Xi meeting could finally end opioids crisis in the US; and recent ASX biotech winners
Health & Biotech
ScoPo’s (actually Wilkie’s) Powerplays: Yoga = chill. Fact. And ASX health stocks up for second week
News
ASX Small Caps and IPO Weekly Wrap: Up days, down days = flat week; Medtech multiplies its mojo
Health & Biotech
ASX Health Stocks: AVITA flies as high as 24pc after providing a big, bullish guidance
News
Rise and Shine: Everything you need to know before the ASX opens
News
ASX Small Cap Lunch Wrap: Healthcare stocks lead some frankly marvellous ASX gains on Thursday
News
Rise and Shine: Everything you need to know before the ASX opens
News
Closing Bell: Local markets close lower as RBA bites before Christmas
Health & Biotech
ASX Health Stocks: PYC on the same page with FDA, Cleo’s cancer test peer-reviewed
Health & Biotech
ASX Health Stocks: Island Pharma granted Aussie patent for flavivirus infection drug, ISLA-101
Health & Biotech
ASX Health Stocks: Althea’s cannabis oil approved for reimbursement in Ireland, Imugene begins Phase 1 trial
News
Imugene: We need to talk about bloody cancer, and then kill it
Explainers
ASX cancer stocks guide: Here’s everything you need to know
News
CLOSING BELL: Local markets dragged lower by central bank angst; lithium minnows and New Hope offer some hope
Health & Biotech
ASX Health Stocks: Lumos granted US FDA emergency-use approval for virus test kit, ViraDx
News
Top 10 at 10: Orexplore lands big fish, inking $1.55m commercial agreement with BHP
Health & Biotech